8-K: Sharps Tech Settles Litigation, Divests Hungarian Unit

Sharps Technology, Inc. has settled ongoing litigation with Barry Berler and Plasto entities, divesting its Hungarian subsidiary and certain assets, resulting in improved pro forma operating results.

Summary

• Sharps Technology, Inc. (STSS) entered into a confidential settlement agreement on October 6, 2025, with Barry Berler, Plastomold Industries Ltd, Plasto Design Solutions, Plasto Design Ltd., and Plasto Technology Group LLC.
• The agreement resolves multiple outstanding litigations and an arbitration proceeding, including cases in EDNY and an AAA arbitration.
• Sharps will transfer certain assets, patents, and registered trademarks to Plasto Technology, including the cancellation of 'Sharps Provensa' trademarks.
• Sharps will assign all shares of its wholly-owned Hungarian subsidiary, Safegard Medical Kft (SMK), to Plasto Technology.
• The settlement includes broad mutual releases of claims and a covenant not to sue, with no admission of fault by any party.
• Sharps will bear all filing fees and transfer expenses related to the asset and trademark transfers.
• Pro forma financial information for the six months ended June 30, 2025, shows a reduction in net revenue by $86,642, but an improvement in gross margin by $731,173 and a reduction in total operating expenses by $818,161.
• Pro forma net income for the six months ended June 30, 2025, improved by $1,590,686, leading to a pro forma net income per share of $13.48, up from $10.45 as reported.
• The divestiture results in a pro forma reduction of total assets by $7,581,631 and total liabilities by $204,709, with a net impact of a $7,376,922 reduction in stockholders' equity as of June 30, 2025.

Sentiment

Score: 7

Explanation: The settlement resolves significant litigation and improves pro forma operating metrics, indicating a positive step towards operational efficiency and reduced legal risk. However, the divestiture of a subsidiary and certain IP, along with a reduction in total assets and equity, presents a mixed picture. The potential for a 'Sell-On Payment' offers future upside.

Positives

• Resolution of multiple ongoing litigations and an arbitration, reducing legal overhead and uncertainty.
• Improved pro forma gross margin by $731,173 and operating loss by $1,549,334 for the six months ended June 30, 2025, due to the divestiture.
• Pro forma net income for the six months ended June 30, 2025, increased by $1,590,686, and diluted EPS improved from $10.45 to $13.48.
• Potential for a 15% 'Sell-On Payment' to Sharps if the Purchaser transfers the assigned patents or undergoes a Change of Control.
• Right to negotiate distribution for any products developed using the assigned patents.
• Elimination of liabilities associated with the divested Hungarian subsidiary (SMK) and related operations post-closing.

Negatives

• Divestiture of a wholly-owned subsidiary (Safegard Medical Kft) and certain assets, patents, and trademarks.
• Pro forma reduction in net revenue by $86,642 for the six months ended June 30, 2025.
• Significant reduction in total assets by $7,581,631 and stockholders' equity by $7,376,922 on a pro forma basis as of June 30, 2025.
• Sharps will bear all filing fees and transfer expenses for the divested assets.
• Barry Berler, a former co-founder and CTO, is involved in the acquiring entity, Plasto Technology Group LLC, which could imply a loss of key intellectual property or operational capacity.

Risks

• The 'Sell-On Payment' is contingent on future events (transfer or Change of Control) and its value is subject to agreement or valuation, introducing uncertainty.
• Sharps has no right to use the assigned patent rights, potentially limiting future product development or market reach in areas covered by those patents.
• Sharps assumes pre-closing ordinary course operating liabilities of SMK and certain non-ordinary course liabilities unknown as of the Effective Date and asserted by unaffiliated third parties on or prior to March 31, 2026.
• The 'AS IS, WHERE IS' transfer of SMK shares and assets, with limited representations, shifts significant risk to the Purchaser but also means Sharps has limited recourse if issues arise post-transfer related to pre-closing conditions not covered by the specific representations.
• The cancellation of 'Sharps Provensa' trademarks could impact brand recognition or future product naming strategies.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the terms of the settlement, which include a potential 15% 'Sell-On Payment' to Sharps if the Purchaser transfers the assigned patents or undergoes a Change of Control, and a right for Sharps to negotiate distribution for any products developed using the assigned patents.

Management Comments

• The Company, Mr. Berler, Plasto and Plasto Technology have agreed to unconditionally and irrevocably release and discharge each other and their respective representatives from and against any and all claims alleged in the Litigation.
• Neither party's entry into the Settlement Agreement shall be deemed an admission of fault, responsibility, or liability for any claim alleged in the Litigation.

Industry Context

The medical device industry, particularly in sharps safety and injection technologies, is highly competitive and subject to intellectual property disputes. Resolving significant litigation and streamlining operations by divesting a non-core or underperforming subsidiary can allow a company to refocus on its primary business and improve financial efficiency. The involvement of a former co-founder and CTO in the acquiring entity suggests a potential spin-off or transfer of specific technology lines.

Comparison to Industry Standards

• The divestiture of a subsidiary and associated assets to resolve litigation is a common strategy for companies to streamline operations and reduce legal burdens, aligning with practices seen in various industries facing complex legal challenges.
• The 'AS IS, WHERE IS' transfer of assets is standard in such dispositions, limiting the seller's post-closing liability, a common risk mitigation strategy.
• The inclusion of a 'Sell-On Payment' clause for assigned intellectual property is a common mechanism to allow the divesting company to participate in future upside, especially when the immediate value is uncertain or the divesting company needs to reduce its direct involvement, similar to earn-out provisions in M&A.
• The pro forma improvements in gross margin and operating loss, despite a revenue reduction, suggest that the divested operations were a drag on profitability, aligning with industry best practices of shedding unprofitable segments to enhance overall financial health.

Corporate Governance

Legal Proceedings

• Barry Berler v. Sharps Technology, Inc. and Alan Blackman; Sharps Technology, Inc. v. Plasto Design Ltd., Plasto Design Solutions, and Plastomold Industries Ltd., EDNY, case no. 2:24-cv-04787 JMW-GRB.
• Plastomold Industries Ltd. v. Sharps Technology, Inc., EDNY, case number 2:24-CV-02580.
• Barry Berler v. Sharps Technology, Inc., AAA Case No.: 01-24-0006-0242 (arbitration).

Related Party Transactions

• The settlement involves Barry Berler, a former co-founder and chief technology officer of Sharps, and Plasto Technology Group LLC, which is designated by Mr. Berler and Plasto. This constitutes a related party transaction due to Berler's prior association and the nature of the settlement involving asset transfers and mutual releases.

Stakeholder Impact

• Shareholders: Reduced legal uncertainty and improved pro forma operating metrics could be positive. However, the divestiture of assets and a subsidiary, along with a reduction in total equity, might be viewed cautiously. The potential for a 'Sell-On Payment' offers future upside.
• Management: Resolution of litigation allows management to focus on core business operations without the distraction and cost of ongoing legal battles.
• Employees: No direct impact on Sharps' current employees is mentioned, but employees of the divested Hungarian subsidiary (SMK) will now be under Plasto Technology Group LLC.
• Customers/Suppliers: The cancellation of 'Sharps Provensa' trademarks and transfer of certain patents could affect product lines or supply chains related to those specific assets, potentially requiring adjustments for affected parties.

Next Steps

• Execution and delivery of definitive agreements, including a Bill of Sale, Patent Assignment Agreement, Trademark Assignment Agreement, and the SMK Assignment.
• Filing of Stipulations of Dismissal with prejudice for all legal proceedings.
• Purchaser to file patent assignments with governmental authorities and maintain assigned patents.
• Sharps to take commercially reasonable steps to terminate and cancel 'Sharps Provensa' trademarks.
• Parties to cooperate on due diligence for asset transfers.
• Sharps to provide reasonable access to the SMK facility for Purchaser's due diligence.
• Sharps to assign equipment owned by Sharps at the SMK facility to SMK prior to the SMK shares transfer.
• SMK assets listed on Schedule 3 to be assigned to Sharps prior to the SMK Assignment closing.
• If elected, enter into a definitive agreement for the relationship between Sharps/SMK and Stericare.

Key Dates

Recommendation

The resolution of significant litigation and the resulting pro forma improvements in operating metrics are positive, reducing uncertainty and streamlining operations. However, the divestiture of a subsidiary and certain intellectual property, coupled with a notable reduction in total assets and equity, presents a mixed financial picture. While the potential for a 'Sell-On Payment' offers future upside, the immediate impact is a smaller asset base. Investors should hold to observe how the company leverages its streamlined structure and remaining assets to drive future growth and profitability, especially given the reduction in revenue from the divested entity.

Keywords

Sharps Technology, STSS, SEC filing, 8-K, settlement agreement, litigation, asset disposition, divestiture, Safegard Medical Kft, Hungarian subsidiary, patents, trademarks, pro forma financials, Barry Berler, Plasto, corporate governance, financial reporting, legal settlement